Sylvie Hauert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sylvie Hauert has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Melody A. Swartz
Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL, 60637, United States; Committee on Immunology, University of Chicago, Chicago, IL, 60637, United States; Committee on Cancer Biology, University of Chicago, Chicago, IL, 60637, United States; Ben May Department of Cancer Research, University of Chicago, Chicago, IL, 60637, United States
2 shared publications - Amanda W. Lund
Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
1 shared publication - Christopher Tremblay
Global Health Institute, Life Sciences Faculty, EPFL, Lausanne, Switzerland
1 shared publication - Daniel E. Speiser
Department of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland
1 shared publication - Douglas Hanahan
Swiss Institute for Experimental Cancer Research (ISREC), EPFL, Lausanne, Switzerland
1 shared publication - Elena M. Cabello
Institute of Medical Genetics, University of Zurich, Zurich, Switzerland
1 shared publication
Latest Publications
- Open Access
- 26 March 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (13) , eabe4362
Lymphangiogenesis-inducing vaccines elicit potent and long-lasting T cell immunity against melanomas
New approach for immune cell recruitment in therapeutic anticancer vaccines drives antigenically broad and long-lasting immunity.
- 26 March 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (13) , eabe4362
Open AccessLymphangiogenesis-inducing vaccines elicit potent and long-lasting T cell immunity against melanomas
New approach for immune cell recruitment in therapeutic anticancer vaccines drives antigenically broad and long-lasting immunity.
- Top Cited PapersOpen Access
- 13 September 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (407) , eaal4712
Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma
Tumor lymphangiogenesis, a driver of immunosuppression and metastasis, also potentiates immunotherapy.
- 13 September 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (407) , eaal4712
Top Cited PapersOpen AccessTumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma
Tumor lymphangiogenesis, a driver of immunosuppression and metastasis, also potentiates immunotherapy.